Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AMLX

AMLX - Amylyx Pharmaceuticals, Inc. Stock Price, Fair Value and News

$14.50-0.97 (-6.27%)
Market Closed

16/100

AMLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

16/100

AMLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$12.61

Target 3M

$14.18

Target 6M

$13.4

AMLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AMLX Price Action

Last 7 days

-14.3%

Last 30 days

19.0%

Last 90 days

3.2%

Trailing 12 Months

320.3%

AMLX RSI Chart

AMLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AMLX Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-10.67

Price/Sales (Trailing)

15.65

EV/EBITDA

-9.15

Price/Free Cashflow

-10.31

AMLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$12.61

Target 3M

$14.18

Target 6M

$13.4

AMLX Fundamentals

AMLX Revenue

Revenue (TTM)

87.4M

AMLX Earnings

Earnings (TTM)

-149.3M

Earnings Growth (Yr)

52.7%

Earnings Growth (Qtr)

17.03%

AMLX Profitability

EBT Margin

-171.59%

Return on Equity

-44.96%

Return on Assets

-41.15%

Free Cashflow Yield

-9.7%

AMLX Investor Care

Shares Dilution (1Y)

60.21%

Diluted EPS (TTM)

-1.79

AMLX Alerts

  • 1 major insider buys and 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024398.0M294.5M190.9M87.4M
2023111.9M201.5M291.1M380.8M
20220011.3M22.2M
2021000285.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Amylyx Pharmaceuticals, Inc.

AMLX
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://amylyx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES338

Amylyx Pharmaceuticals, Inc. Frequently Asked Questions

AMLX is the stock ticker symbol of Amylyx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Amylyx Pharmaceuticals, Inc. is 1.59 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AMLX's fair value in chart for subscribers.

The fair value guage provides a quick view whether AMLX is over valued or under valued. Whether Amylyx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Amylyx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMLX.

As of Wed Jan 28 2026, AMLX's PE ratio (Price to Earnings) is -10.67 and Price to Sales (PS) ratio is 15.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMLX PE ratio will change depending on the future growth rate expectations of investors.